Brief: Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)

OncoSec Medical Incorporated

03/04/2023 12:31

April 3 (Reuters) - OncoSec Medical Inc  ONCS.O :
    * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL
ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)
IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1
TREATMENT
    * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST
V1.1
ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT
MET IN STUDY
    * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN
COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA
SETTING
    * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2
RANDOMIZED
TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING
IS SCHEDULED IN MAY

Source text for Eikon:  ID:nPn3787qZa 
Further company coverage:  ONCS.O 

 ((reuters.briefs@thomsonreuters.com;))